Fierce Biotech Layoff Tracker: Agios slims R&D operations, Spero cuts after tough FDA callnews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: Agios slims R&D operations, Scholar Rock in a hard placenews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: Genocea closes up shop, Applied axes 40% of staffnews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Fierce Biotech Layoff Tracker: Atreca culls workforce in reorganization; Genocea closes up shopnews2022-03-31T20:21:36+00:00March 31st, 2022|FierceBiotech|
Chutes & Ladders—John Mascola departs NIAID’s Vaccine Research Center after 22 yearsnews2022-03-31T18:34:27+00:00March 31st, 2022|FierceBiotech|
Vertex gets proof-of-concept for non-opioid painkiller, clearing way for pivotal studiesnews2022-03-31T14:59:21+00:00March 31st, 2022|FierceBiotech|
Reuniting the band: Former Merck CEO follows 3 former colleagues to Eikonnews2022-03-31T13:38:23+00:00March 31st, 2022|FierceBiotech|
Taysha lays off 35% of staff, narrows R&D focus to keep funding its top gene therapiesnews2022-03-31T12:00:17+00:00March 31st, 2022|FierceBiotech|
Ono pulls trigger on deal for multispecific antibody against ‘very challenging’ cancer targetnews2022-03-31T10:39:50+00:00March 31st, 2022|FierceBiotech|
CytoDyn’s leronlimab slapped with FDA holds for COVID-19, HIV programsnews2022-03-30T21:50:21+00:00March 30th, 2022|FierceBiotech|
